Baxter, Flamel Sign Collaboration Agreement

Baxter and Flamel Technologies have entered into an agreement to formulate controlled release applications of blood clotting factor replacement therapies, using Flamel’s Medusa Technology. The two companies will focus on developing longer-acting formulations, with the objective of reducing the frequency of infusions required to treat blood clotting disorders in hemophilia.

Pursuant to the agreement between the two companies, Flamel will receive technology access fees totaling E2.5 million. Baxter will pay all development costs for the program and have an exclusive right to negotiate a license to the Medusa platform.

Hartmut Ehrlich, Vice President of global research and development in BioScience at Baxter, said: “We continue to develop and advance novel therapies that improve patient convenience by decreasing the frequency of infusions to help people living with hemophilia lead a more normal life. We look forward to this partnership using Flamel’s Medusa® Technology as a novel approach to address this goal.”

Stephen Willard, CEO of Flamel, said: “We are pleased to be working with Baxter to develop longer-acting formulations of factor replacement therapies for hemophilia patients.”

“Baxter is an ideal partner for these molecules due to its extensive expertise in the field. Our work with Baxter allows us to leverage our expertise in drug delivery to create solutions for the administration of intravenous formulations of therapeutic proteins. This program has the potential to develop more convenient solutions for people living with hemophilia, their families, and physicians,” he added.